bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
PATHTSOD7040

Order Name (ชื่อการทดสอบ):
IDH 1/2 mutation (Outside lab)

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Paraffin embedded tissue block
 
Turnaround Time (ระยะเวลารอผล):
2-3 weeks
 
Useful For (ประโยชน์การทดสอบ):
1. Supporting a morphological diagnosis of a diffuse glioma
2. Assisting in central nervous system tumor classification
3. Stratifying prognosis of diffuse gliomas
4.Supporting the differential diagnosis of chondroid bone tumors
Stratifying prognosis of acute myeloid leukemia
 
Methodology (วิธีการทดสอบ):
Polymerase Chain Reaction (PCR)-Based Next-Generation Sequencing
 
 
 
Test Code (รหัสการทดสอบ):
PATHTSOD7040

Order Name (ชื่อการทดสอบ):
IDH 1/2 mutation (Outside lab)

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Paraffin embedded tissue block
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Paraffin embedded tissue block
 
Sub Mission Container (ภาชนะส่งตรวจ):
Paraffin embedded tissue block
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Specimens that have been decalcified (all methods); specimens that have not been formalin-fixed, paraffin-embedded; bone marrow in EDTA
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
 
Specimen Type Temperature
Paraffin embedded tissue block Room temperature
 
 
 
Test Code (รหัสการทดสอบ):
PATHTSOD7040

Order Name (ชื่อการทดสอบ):
IDH 1/2 mutation (Outside lab)

 
Schedule (ตารางการทดสอบ):
Tested daily, at 08:00 am. - 06:00 pm.
 
Turnaround Time (ระยะเวลารอผล):
2-3 weeks
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Surgical Pathology, Laboratory Department Tel.14146
 
 
 
Test Code (รหัสการทดสอบ):
PATHTSOD7040

Order Name (ชื่อการทดสอบ):
IDH 1/2 mutation (Outside lab)

 
 
Clinical Information (ข้อมูลทางคลินิก):
IDH1 and IDH2 (IDH) genes encode dehydrogenase enzymes that are involved in cellular glucose metabolism and oxidative damage control. IDH mutations, primarily involving codons R132 in IDH1 and R172 in IDH2, result in reduction of the enzyme physiological activity and gain of a neomorphic ability to generate oncometabolite R(-)-2-hydroxyglutarate, which contribute to tumorigenesis by altering numerous cellular responses, including genome-wide epigenetic changes that characterize the glioma CpG island methylator phenotype (G-CIMP). IDH mutations seem to be an early event in gliomagenesis and have been identified in over 70% of lower-grade (grades II/III) diffuse gliomas and secondary glioblastoma. These mutations are rarely seen in other central nervous system tumors and are not seen in reactive non-neoplastic processes, and define a group of lower and high-grade diffuse gliomas associated with a more favorable prognosis. Assessment of IDH mutation status in central nervous system tumors may assist in tumor classification and provide prognostically relevant information for subgroups of patients with diffuse gliomas

IDH1 and IDH2 gene mutations are also observed in a variety of non-CNS tumor types. Assessment of IDH mutation status may assist in the differential diagnosis of chondroid bone tumors and provide prognostically relevant information in other contexts, such as in the setting of acute myeloid leukemia (AML)
 
Clinical Reference (เอกสารอ้างอิง):
1. https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/92361
(Retrived 19 MAR 19)